Assessing Replication-Stress Sensitivity in Breast Cancer Cells
Complete the form below to unlock access to ALL audio articles.
Oncotarget published "Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity" which reported that these authors recently documented that gain-of-function mutant p53 R273H in triple negative breast cancer cells interacts with replicating DNA and PARP1. The missense R273H GOF mtp53 has a mutated central DNA binding domain that renders it unable to bind specifically to DNA, but maintains the capacity to interact tightly with chromatin.
Both the C-terminal domain and oligomerization domain of GOF mtp53 proteins are intact and it is unclear whether these regions of mtp53 are responsible for chromatin-based DNA replication activities.
These included a frame-shift mtp53 R273Hfs387, which depleted mtp53 protein expression; mtp53 R273HΔ381-388, which had a small deletion within the CTD; and mtp53 R273HΔ347-393, which had both the OD and CTD regions truncated.
The mtp53 R273HΔ347-393 existed exclusively as monomers and disrupted the chromatin interaction of mtp53 R273H.
Taken together these Oncotarget findings show that the CTD and OD domains of mtp53 R273H play critical roles in mutant p53 GOF that pertain to processes associated with DNA replication.
Dr. Jill Bargonetti said "The p53 tumor suppressor protein is well known as a transcription factor but p53 also has transcription independent functions."
While tumor-derived missense mtp53 proteins have altered functions they contain the two N-terminal transactivation domains, followed by a proline rich domain, an altered central DNA binding domain, and the oligomerization domain and the C-terminal regulatory domain.
Herein they further examine the ability of mtp53 R273H, and its OD and CTD regions, to influence cell proliferation, DNA replication, and cell cycle progression of breast cancer cells.
The choice to investigate a potential role for the OD and CTD domains within the context of the mtp53 R273H allele was two-fold:
They delineated the above GOF pathway in this background and in parallel with the studies reported, worked to generate more tools to elucidate the role of each domain in mtp53 GOF activity;
Their pursuit of a genetic approach using CRISPR-Cas9 technology to create specific alterations within each domain necessitated that we focus first on one mtp53 R273H expressing-cell line.
They saw that a frameshift mutation in C-terminal end of mtp53 reduced stable mtp53 R273H protein levels compared to the parental MDA-MB-468 cells, reduced cell proliferation, and reduced the chromatin association of replication proteins that mirrored their slow progression through S-phase.
The CRISPR-Cas9 targeting also produced cell clones with C-terminal truncated mtp53 R273H proteins; such cells with truncated mtp53 R273H showed decreased proliferation as compared to the parental cells but progressed through S phase in a similar manner.
The Bargonetti Research Team concluded in their Oncotarget Research Output that their current studies do not point to a specific function executed by the OD and CTD domains in response to thymidine; however, they can show that their loss does not impact replisome assembly at the onset of S-phase as measured by PCNA chromatin loading and they will address this finding in the future.
Thus, OD and CTD domain function(s) correlate with events post S-phase entry, in contrast with that function conferred by other p53 domain(s) deficient in the mtp53fs387 cell line, whose loss impedes S-phase entry. Although currently the authors are unable to articulate the precise roles of these distinct regions of p53 in response to thymidine, their studies suggest that they may function at temporally distinct stages of S-phase.
Reference: Ellison V, Annor GK, Freedman C, et al. Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity. Oncotarget. 2021;12(12):1128-1146. doi: 10.18632/oncotarget.27975
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.